Amgen has announced a phase-three study analyzing how XGEVA competes with zoledronic acid when it comes to meeting the primary endpoint of non-inferiority in delaying the time to first on-study skeletal-related event (SRE) in patients with multiple myeloma.
According to the test, the drug did not meet the secondary endpoints of superiority in delaying time to first SRE and delaying time to first-and-subsequent SRE.
Adverse effects of XGEVA noted in the study include diarrhea and nausea.
“Bone complications like fracture, spinal cord compression and radiation or surgery to bone are devastating for multiple myeloma patients," Dr. Sean Harper, executive vice president of research and development at Amgen, said. "Many of these patients suffer from renal impairment, which has limited their treatment options. XGEVA's unique mechanism of action has the potential to prevent bone complications in multiple myeloma patients regardless of their renal status, fulfilling an important unmet medical need."
